Cosmos Health Inc. Signs Major CBD Manufacturing Deal with Humacology
Cosmos Health Inc. (NASDAQ:COSM) has announced a groundbreaking contract manufacturing agreement with Australia's Humacology, a leading provider of CBD therapies. Under this deal, Cana Laboratories, a subsidiary of Cosmos Health, will produce up to 500,000 units of Humacology's CBD products. This marks the second significant contract for Cosmos Health in recent times, following their partnership with Provident Pharmaceuticals to manufacture 4.32 million units of DE3-SOLE, a vitamin D absorption aid.
Humacology, known for its innovative CBD products and recent Cannabiz Award for Innovation, is thrilled about the collaboration with Cana Laboratories. Cosmos Health's CEO, Greg Siokas, hinted at more profitable manufacturing contracts in the pipeline and promised to unveil further developments soon.
Established in 2009, Cosmos Health boasts a diverse portfolio of pharmaceutical and nutraceutical brands, along with a telehealth platform acquired through ZipDoctor, Inc. Their manufacturing facility is European GMP licensed and certified by the European Medicines Agency, enabling them to distribute healthcare products across Europe, Asia, and North America.
The company's strategic growth strategy involves R&D partnerships targeting major health disorders, as well as the creation of patented nutraceuticals and complex generics. With a presence in Greece and the UK, Cosmos Health is expanding its global footprint.
In conclusion, Cosmos Health's latest partnership with Humacology signifies a significant milestone in their contract manufacturing business. The company's focus on innovation and global expansion bodes well for their future growth prospects and investor confidence. Stay tuned for more updates on Cosmos Health's promising trajectory in the healthcare industry.